Posted by Michael Wonder on 22 Apr 2020
FDA approves new therapy for triple negative breast cancer that has spread, not responded to other treatments
22 April 2020 - Today, the U.S. FDA granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread to other parts of the body.
Patients must have received at least two prior therapies before taking Trodelvy.
The FDA approved Trodelvy based on the results of a clinical trial of 108 patients with metastatic triple-negative breast cancer who had received at least two prior treatments for metastatic disease.
